カテゴリ： Grand View Research, 世界, 医療/バイオ

ワクチンのグローバル市場2023-2030：サブユニット、mRNA

■ 英語タイトル：Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route of Administration (Oral, Nasal), By Disease Indication (HPV, MMR), By Age Group, By Distribution Channel, And Segment Forecasts, 2023 - 2030

調査会社Grand View Research社が発行したリサーチレポート（データ管理コード：GRV23AUG064）■ 発行会社/調査会社：Grand View Research
■ 商品コード：GRV23AUG064
■ 発行日：2023年7月25日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：180
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後3営業日）
■ 販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ワクチンのグローバル市場2023-2030：サブユニット、mRNA]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ワクチン市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界のワクチン市場規模は2030年までに1,146億6,000万米ドルに達する見込みです。同市場は、2023年から2030年にかけて年平均成長率1.4%で拡大する見込みです。成長の背景には、予防接種プログラムの増加や、RSVやクラミジアなどの疾患に対するワクチンの開発があります。公衆衛生上懸念される疾患に対するワクチンへのアクセス改善には大きな進展がありました。多くの新しいワクチンが開発され、世界的に配布されるようになり、その結果、数え切れないほどの命が救われ、さまざまな病気が予防されるようになりました。

さらに、ワクチン市場には、ワクチンへのアクセスを改善し、新しいワクチンを開発し、ワクチンの安全性を確保することを目的としたイニシアチブがいくつかあります。これらのイニシアチブには、国際機関、政府、民間企業、慈善団体が関与しています。これらのイニシアチブは、協調と革新を通じて、世界的な保健上の課題に対処し、公衆衛生の成果を向上させるのに役立っています。例えば、COVAXはCOVIDワクチンへの公平なアクセスを確保することを目的とした世界的なイニシアチブです。このイニシアチブは、Gavi、Vaccine Alliance、世界保健機関（WHO）、およびCoalition for Epidemic Preparedness Innovations（CEPI）が共同で主導しています。

2021年に世界保健機関（WHO）加盟国にワクチンを供給するワクチン製造業者は90社以上ありますが、供給は依然として、多様な展開可能な技術を持ち、世界的なリーチを持つ10社未満の製造業者に大きく依存しています。このような集中は、特にアフリカと東地中海地域において、地域的な供給不安と市場の健康問題につながります。米国では2023年後半にCOVIDワクチン市場が民営化される可能性があると予想されており、この民営化によってCOVIDワクチンの価格が上昇し、他のプレーヤーにも市場が開放される可能性があります。例えば、ModernaとPfizer BioNTechの両社は、それぞれのmRNA COVIDワクチンの価格を1回あたり約110～130米ドルに引き上げる可能性があると発表しています。

ワクチン市場レポートハイライト

- ワクチンの種類別では、mRNA分野が2022年に39.12%のシェアで市場を支配しました。しかし、予測期間中、サブユニットワクチンセグメントがCAGR 8.1%で最速の成長が見込まれます。

- 投与経路別では、非経口投与が予測期間を通じてワクチン市場シェアの大半を占めると予想されます。非経口投与は、他の投与経路と比較して汚染リスクを低減するため、このセグメントの優位性に寄与しています。

- 適応疾患別では、2021年および2022年におけるCOVID-19ワクチンの高い流通量が主因となり、ウイルス性疾患セグメントが2022年のワクチン市場で最大シェアを獲得しました。

- 年齢別では、多くの国で小児期における定期予防接種の一環として特定の予防接種を受けることを義務付ける国家予防接種プログラムが策定されていることから、小児科が予測期間中に最も急成長する見込みです。

- 販売チャネル別では、薬局が最も急速に成長すると予測されています。この成長は、患者にとって利用しやすく利便性が向上すること、薬局にとって収益と利益が増加する可能性があることに起因しています。

- 北米地域は予測期間中に最も速いCAGRで成長する見込みです。この地域は、ファイザー、Moderna、サノフィパスツール、メルクなど少数の主要企業が支配しています。これらの企業は、確立された販売網とワクチン研究開発への多額の投資により、市場で強い存在感を示しています。

第1章. 調査手法＆範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. タイプ別分析
第5章. 投与経路別分析
第6章. 疾患別分析
第7章. 年齢層別分析
第8章. 流通チャネル別分析
第9章. 地域別分析
第10章. 競争状況

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.1.2. Objective – 1
1.1.3. Objective – 2
1.1.4. Objective – 3
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Gvr’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information Or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.7. List Of Secondary Sources
1.8. List Of Abbreviations
1.9. List Of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type and Route of Administration Snapshot
2.3. Disease Indication and Distribution Channel Snapshot
2.4. Age Group Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Rise in the importance of immunization across the globe
3.4.2. Growing Burden of Chronic and Infectious Diseases
3.4.3. Technology advancements in the vaccination development
3.5. Market Restraint Analysis
3.5.1. Lack of healthcare infrastructure
3.5.2. Cost of immunization
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Vaccine Market: Type Movement Analysis
4.2. Subunit Vaccines
4.2.1. Vaccine Market For Subunit Vaccines, 2018 – 2030 (USD Billion)
4.2.2. Recombinant vaccines
4.2.2.1. Vaccine Market For Recombinant vaccines, 2018 – 2030 (USD Billion)
4.2.3. Conjugate Vaccines
4.2.3.1. Vaccine Market For Conjugate vaccines, 2018 – 2030 (USD Billion)
4.2.4. Toxoid vaccines
4.2.4.1. Vaccine Market For Toxoid vaccines, 2018 – 2030 (USD Billion)
4.3. Inactivated
4.3.1. Vaccine Market For Inactivated, 2018 – 2030 (USD Billion)
4.4. Live Attenuated
4.4.1. Vaccine Market For Live Attenuated, 2018 – 2030 (USD Billion)
4.5. mRNA vaccines
4.5.1. Vaccine Market For mRNA vaccines, 2018 – 2030 (USD Billion)
4.6. Viral vector vaccines
4.6.1. Vaccine Market For Viral vector vaccines, 2018 – 2030 (USD Billion)
Chapter 5. Route Of Administration Business Analysis
5.1. Vaccine Market: Route of Administration Movement Analysis
5.2. Oral
5.2.1. Vaccine Market For Oral, 2018 – 2030 (USD Billion)
5.3. Parenteral
5.3.1. Vaccine Market For Parenteral, 2018 – 2030 (USD Billion)
5.4. Nasal
5.4.1. Vaccine Market For Nasal, 2018 – 2030 (USD Billion)
Chapter 6. Disease Indication Business Analysis
6.1. Vaccine Market: Disease Indication Movement Analysis
6.2. Viral Diseases
6.2.1. Vaccine Market For Viral Diseases, 2018 – 2030 (USD Billion)
6.2.2. Hepatitis
6.2.2.1. Vaccine Market For Hepatitis, 2018 – 2030 (USD Billion)
6.2.3. Influenza
6.2.3.1. Vaccine Market For Influenza, 2018 – 2030 (USD Billion)
6.2.4. HPV
6.2.4.1. Vaccine Market For HPV, 2018 – 2030 (USD Billion)
6.2.5. MMR
6.2.5.1. Vaccine Market For MMR, 2018 – 2030 (USD Billion)
6.2.6. Rotavirus
6.2.6.1. Vaccine Market For Rotavirus, 2018 – 2030 (USD Billion)
6.2.7. Herpes Zoster
6.2.7.1. Vaccine Market For Herpes Zoster, 2018 – 2030 (USD Billion)
6.2.8. Covid-19
6.2.8.1. Vaccine Market For Covid-19, 2018 – 2030 (USD Billion)
6.2.9. Others
6.2.9.1. Vaccine Market For Others, 2018 – 2030 (USD Billion)
6.3. Bacterial Vaccines
6.3.1. Vaccine Market For Bacterial Vaccines, 2018 – 2030 (USD Billion)
6.3.2. Meningococcal Diseases
6.3.2.1. Vaccine Market For Meningococcal Diseases, 2018 – 2030 (USD Billion)
6.3.3. Pneumococcal Diseases
6.3.3.1. Vaccine Market For Pneumococcal Diseases, 2018 – 2030 (USD Billion)
6.3.4. DPT
6.3.4.1. Vaccine Market For DPT, 2018 – 2030 (USD Billion)
6.3.5. Others
6.3.5.1. Vaccine Market For Others, 2018 – 2030 (USD Billion)
6.4. Cancer Vaccines
6.4.1. Vaccine Market For Cancer Vaccines, 2018 – 2030 (USD Billion)
6.5. Allergy Vaccines
6.5.1. Vaccine Market For Allergy Vaccines, 2018 – 2030 (USD Billion)
Chapter 7. Age Group Business Analysis
7.1. Vaccine Market: Age Group Movement Analysis
7.2. Pediatric
7.2.1. Vaccine Market For Pediatric, 2018 – 2030 (USD Billion)
7.3. Adult
7.3.1. Vaccine Market For Adult, 2018 – 2030 (USD Billion)
Chapter 8. Distribution Channel Business Analysis
8.1. Vaccine Market: Distribution Channel Movement Analysis
8.2. Hospital & Retail Pharmacies
8.2.1. Vaccine Market For Hospital & Retail Pharmacies, 2018 – 2030 (USD Billion)
8.3. Government Suppliers
8.3.1. Vaccine Market For Government Suppliers 2018 – 2030 (USD Billion)
8.4. Others
8.4.1. Vaccine Market For Others, 2018 – 2030 (USD Billion)
Chapter 9. Regional Business Analysis
9.1. Vaccine Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. North America Vaccines Market 2018 – 2030 (USD Billion)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Regulatory Framework
9.2.2.5. Reimbursement Scenario
9.2.2.6. U.S. Vaccine Market 2018 – 2030 (USD Billion)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. Reimbursement Scenario
9.2.3.6. Canada Vaccine Market 2018 – 2030 (USD Billion)
9.3. Europe
9.3.1. Europe Vaccines Market 2018 – 2030 (USD Billion)
9.3.2. Germany
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. Regulatory Framework
9.3.2.5. Reimbursement Scenario
9.3.2.6. Germany Vaccine Market 2018 – 2030 (USD Billion)
9.3.3. UK
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. Reimbursement Scenario
9.3.3.6. UK Vaccine Market 2018 – 2030 (USD Billion)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Reimbursement Scenario
9.3.4.6. France Vaccine Market 2018 – 2030 (USD Billion)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. Reimbursement Scenario
9.3.5.6. Italy Vaccine Market 2018 – 2030 (USD Billion)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Reimbursement Scenario
9.3.6.6. Spain Vaccine Market 2018 – 2030 (USD Billion)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Reimbursement Scenario
9.3.7.6. Denmark Vaccine Market 2018 – 2030 (USD Billion)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Reimbursement Scenario
9.3.8.6. Sweden Vaccine Market 2018 – 2030 (USD Billion)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Reimbursement Scenario
9.3.9.6. Norway Vaccine Market 2018 – 2030 (USD Billion)
9.4. Asia Pacific
9.4.1. Asia Pacific Vaccine Market, 2018 – 2030 (USD Billion)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Regulatory Framework
9.4.2.5. Reimbursement Scenario
9.4.2.6. Japan Vaccine Market 2018 – 2030 (USD Billion)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Reimbursement Scenario
9.4.3.6. China Vaccine Market 2018 – 2030 (USD Billion)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. Reimbursement Scenario
9.4.4.6. India Vaccine Market 2018 – 2030 (USD Billion)
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. Reimbursement Scenario
9.4.5.6. South Korea Vaccine Market 2018 – 2030 (USD Billion)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Reimbursement Scenario
9.4.6.6. Australia Vaccine Market 2018 – 2030 (USD Billion)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Reimbursement Scenario
9.4.7.6. Thailand Vaccine Market 2018 – 2030 (USD Billion)
9.5. Latin America
9.5.1. Latin America Vaccine Market, 2018 – 2030 (USD Billion)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Regulatory Framework
9.5.2.5. Reimbursement Scenario
9.5.2.6. Brazil Vaccine Market 2018 – 2030 (USD Billion)
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Reimbursement Scenario
9.5.3.6. Mexico Vaccine Market 2018 – 2030 (USD Billion)
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Reimbursement Scenario
9.5.4.6. Argentina Vaccine Market 2018 – 2030 (USD Billion)
9.6. MEA
9.6.1. MEA Vaccine Market, 2018 – 2030 (USD Billion)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. Regulatory Framework
9.6.2.5. Reimbursement Scenario
9.6.2.6. South Africa Vaccine Market 2018 – 2030 (USD Billion)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. Reimbursement Scenario
9.6.3.6. Saudi Arabia Vaccine Market 2018 – 2030 (USD Billion)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Reimbursement Scenario
9.6.4.6. UAE Vaccine Market 2018 – 2030 (USD Billion)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. Reimbursement Scenario
9.6.5.6. Kuwait Vaccine Market 2018 – 2030 (USD Billion)
Chapter 10. Competitive Landscape
10.1. Participant’s overview
10.2. Financial performance
10.3. Participant categorization
10.3.1. Market Leaders
10.3.2. Vaccine Market Share Analysis, 2022
10.3.3. Company Profiles
10.3.3.1. Serum Institute of India Pvt. Ltd.
10.3.3.1.1. Company Overview
10.3.3.1.2. Financial Performance
10.3.3.1.3. Product Benchmarking
10.3.3.1.4. Strategic Initiatives
10.3.3.2. Seqirus
10.3.3.2.1. Company Overview
10.3.3.2.2. Financial Performance
10.3.3.2.3. Product Benchmarking
10.3.3.2.4. Strategic Initiatives
10.3.3.3. Sanofi
10.3.3.3.1. Company Overview
10.3.3.3.2. Financial Performance
10.3.3.3.3. Product Benchmarking
10.3.3.3.4. Strategic Initiatives
10.3.3.4. GSK Plc.
10.3.3.4.1. Company Overview
10.3.3.4.2. Financial Performance
10.3.3.4.3. Product Benchmarking
10.3.3.4.4. Strategic Initiatives
10.3.3.5. Merck & Co., Inc.
10.3.3.5.1. Company Overview
10.3.3.5.2. Financial Performance
10.3.3.5.3. Product Benchmarking
10.3.3.5.4. Strategic Initiatives
10.3.3.6. Pfizer Inc.
10.3.3.6.1. Company Overview
10.3.3.6.2. Financial Performance
10.3.3.6.3. Product Benchmarking
10.3.3.6.4. Strategic Initiatives
10.3.3.7. Moderna Inc.
10.3.3.7.1. Company Overview
10.3.3.7.2. Financial Performance
10.3.3.7.3. Product Benchmarking
10.3.3.7.4. Strategic Initiatives
10.3.3.8. Sinovac
10.3.3.8.1. Company Overview
10.3.3.8.2. Financial Performance
10.3.3.8.3. Product Benchmarking
10.3.3.8.4. Strategic Initiatives
10.3.3.9. BioNTech SE
10.3.3.9.1. Company Overview
10.3.3.9.2. Financial Performance
10.3.3.9.3. Product Benchmarking
10.3.3.9.4. Strategic Initiatives
10.3.3.10. AstraZeneca
10.3.3.10.1. Company Overview
10.3.3.10.2. Financial Performance
10.3.3.10.3. Product Benchmarking
10.3.3.10.4. Strategic Initiatives
10.3.4. Strategy Mapping
10.3.4.1. Expansion
10.3.4.2. Acquisition
10.3.4.3. Collaborations
10.3.4.4. Product/Service Launch
10.3.4.5. Partnerships
10.3.4.6. Others

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Vaccine Market, by Region, 2018 - 2030 (USD Billion)
Table 4 Global Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 5 Global Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 6 Global Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 7 Global Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 8 Global Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 9 North America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
Table 10 North America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 11 North America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 12 North America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 13 North America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 14 North America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 15 U.S. Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 16 U.S. Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 17 U.S. Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 18 U.S. Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 19 U.S. Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 20 Canada Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 21 Canada Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 22 Canada Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 23 Canada Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 24 Canada Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 25 Europe Vaccine Market, by Country, 2018 - 2030 (USD Billion)
Table 26 Europe Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 27 Europe Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 28 Europe Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 29 Europe Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 30 Europe Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 31 Germany Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 32 Germany Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 33 Germany Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 34 Germany Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 35 Germany Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 36 UK Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 37 UK Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 38 UK Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 39 UK Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 40 UK Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 41 France Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 42 France Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 43 France Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 44 France Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 45 France Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 46 Italy Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 47 Italy Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 48 Italy Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 49 Italy Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 50 Italy Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 51 Spain Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 52 Spain Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 53 Spain Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 54 Spain Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 55 Spain Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 56 Denmark Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 57 Denmark Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 58 Denmark Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 59 Denmark Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 60 Denmark Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 61 Sweden Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 62 Sweden Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 63 Sweden Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 64 Sweden Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 65 Sweden Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 66 Norway Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 67 Norway Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 68 Norway Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 69 Norway Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 70 Norway Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 71 Asia Pacific Vaccine Market, by Country, 2018 - 2030 (USD Billion)
Table 72 Asia Pacific Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 73 Asia Pacific Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 74 Asia Pacific Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 75 Asia Pacific Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 76 Asia Pacific Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 77 China Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 78 China Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 79 China Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 80 China Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 81 China Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 82 Japan Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 83 Japan Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 84 Japan Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 85 Japan Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 86 Japan Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 87 India Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 88 India Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 89 India Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 90 India Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 91 India Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 92 South Korea Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 93 South Korea Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 94 South Korea Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 95 South Korea Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 96 South Korea Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 97 Australia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 98 Australia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 99 Australia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 100 Australia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 101 Australia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 102 Thailand Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 103 Thailand Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 104 Thailand Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 105 Thailand Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 106 Thailand Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 107 Latin America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
Table 108 Latin America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 109 Latin America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 110 Latin America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 111 Latin America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 112 Latin America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 113 Brazil Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 114 Brazil Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 115 Brazil Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 116 Brazil Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 117 Brazil Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 118 Mexico Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 119 Mexico Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 120 Mexico Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 121 Mexico Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 122 Mexico Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 123 Argentina Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 124 Argentina Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 125 Argentina Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 126 Argentina Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 127 Argentina Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 128 Middle East & Africa Vaccine Market, by Country, 2018 - 2030 (USD Billion)
Table 129 Middle East & Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 130 Middle East & Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 131 Middle East & Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 132 Middle East & Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 133 Middle East & Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 134 South Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 135 South Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 136 South Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 137 South Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 138 South Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 139 Saudi Arabia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 140 Saudi Arabia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 141 Saudi Arabia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 142 Saudi Arabia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 143 Saudi Arabia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 144 UAE Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 145 UAE Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 146 UAE Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 147 UAE Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 148 UAE Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 149 Kuwait Vaccine Market, by Type, 2018 - 2030 (USD Billion)
Table 150 Kuwait Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
Table 151 Kuwait Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
Table 152 Kuwait Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
Table 153 Kuwait Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
Table 154 Financial performance
Table 155 Key companies undergoing expansions
Table 156 Key companies undergoing acquisitions
Table 157 Key companies undergoing collaborations
Table 158 Key companies launching new products/services
Table 159 Key companies undergoing partnerships
Table 160 Key companies undertaking other strategies

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 豚サーコウイルス2型（PCV2）ワクチンのグローバル市場2023：WHタイプ、LGタイプ、SHタイプ、SDタイプ、ZJ Cタイプ、その他
  • 世界の生物製剤市場2023-2030：市場規模、シェア、動向分析
  • mRNAワクチンコア酵素のグローバル市場2023：mRNAキャッピング酵素、mRNA T7ポリメラーゼ、無機ピロホスファターゼ、2’O-メチルトランスフェラーゼ、その他
  • 微生物APIのグローバル市場2023-2030：哺乳類、細菌、真菌
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GRV23AUG064 )"ワクチンのグローバル市場2023-2030：サブユニット、mRNA" (英文：Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route of Administration (Oral, Nasal), By Disease Indication (HPV, MMR), By Age Group, By Distribution Channel, And Segment Forecasts, 2023 - 2030)はGrand View Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。